NAPROXEN ORAL SUSPENSION, USP, 125 mg/5mL, Rx only, 16fl oz (473 mL) bottles, Distributed by: Acella Pharmaceuticals, LLC, Alpharetta, GA 30005, Made in Canada NDC 42192-619-16 Recall

Ongoing
Drugs
Class II — Moderate

Recall Date

May 13, 2026

Company

Acella Pharmaceuticals, LLC

Source

FDA

Units

6,336 bottles

Reason: Chemical contamination; presence of lead and lithium above specification

Class II: Use of the product may cause temporary or medically reversible health problems.

Official FDA recall notice

Information is from official FDA notices. Do not stop taking any medication without consulting your doctor or pharmacist first — the risks of stopping may be greater than the risk from the recalled product.

Recall Details

Description

Chemical contamination; presence of lead and lithium above specification

Reason for Recall

Chemical contamination; presence of lead and lithium above specification

Product: NAPROXEN ORAL SUSPENSION, USP, 125 mg/5mL, Rx only, 16fl oz (473 mL) bottles, Distributed by: Acella Pharmaceuticals, LLC, Alpharetta, GA 30005, Made in Canada NDC 42192-619-16
Official Recall ID: FDA-DRUG-D-0523-2026
Units affected: 6,336 bottles

What Should I Do?

Check your lot number. Don't stop taking a prescribed medication without talking to your pharmacist or doctor. Contact the pharmacy where you got it about a replacement.

Quantity: 6,336 bottles

Remediation GuideAction Required

5-step guide to help you action required this recalled product. Click Start Remediation to track your progress.

1
Confirm Your Product Is Affected
2
Read the Full Recall Notice
3
Stop Using the Product if in Doubt

+2 more steps…

View Official Recall Notice (FDA)

Last updated May 19, 2026

Injured by a recalled product?

Our legal partners offer free consultations for recall victims.

Get Free Legal Help →Sponsored

Stay Informed

Weekly recall digest — free, no spam.